Background Recent circumstantial evidence suggests that an increasing number of Iranian patients with cutaneous leishmaniasis are unresponsive to meglumine antimoniate (Glucantime), the first line of treatment in Iran. This study was designed to determine whether the clinical responses (healing, or non-healing) were correlated with the susceptibility of Leishmania parasites to Glucantime. Methods and Findings In vitro susceptibility testing was first performed on 185 isolated parasites in the intracellular mouse peritoneal macrophage model. A strong correlation between the clinical outcome and the in vitro effective concentration 50% (EC50) values was observed. Parasites derived from patients with non-healing lesions had EC50 values at least 4-fold higher than parasites derived from lesions of healing patients. A selection of these strains was typed at the molecular level by pulsed-field gels and by sequencing the pteridine reductase 1 (PTR1) gene. These techniques indicated that 28 out of 31 selected strains were Leishmania tropica and that three were Leishmania major. The L. major isolates were part of a distinct pulsed-field group, and the L. tropica isolates could be classified in three related additional pulsed-field groups. For each pulsed-field karyotype, we selected sensitive and resistant parasites in which we transfected the firefly luciferase marker to assess further the in vitro susceptibility of field isolates in the monocyte cell line THP1. These determinations confirmed unequivocally that patients with non-healing lesions were infected with L. tropica parasites resistant to Glucantime. Additional characterization of the resistant isolates showed that resistance is stable and can be reversed by buthionine sulfoximine, an inhibitor of glutathione biosynthesis. Conclusions To the authors' knowledge, this is the first report of proven resistant parasites contributing to treatment failure for cutaneous leishmaniasis and shows that primary Glucantime-resistant L. tropica field isolates are now frequent in Iran.
Guerin PJ, Olliaro P, Sundar S, Boelaert M, Croft SL, et al. (2002) Visceral leishmaniasis: Current status of control, diagnosis, and treatment, and a proposed research and development agenda. Lancet Infect Dis 2: 494–501.
[3]
Murray HW, Berman J, Davies CR, Saravia NG (2005) Advances in leishmaniasis. Lancet 366: 1561–1577.
[4]
Sundar S, More DK, Singh MK, Singh VP, Sharma S, et al. (2000) Failure of pentavalent antimony in visceral leishmaniasis in India: Report from the Center of the Indian Epidemic. Clin Infect Dis 31: 1104–1107.
[5]
Sundar S, Jha TK, Thakur CP, Engel J, Sindermann H, et al. (2002) Oral miltefosine for Indian visceral leishmaniasis. N Engl J Med 347: 1739–1746.
[6]
Lira R, Sundar S, Makharia A, Kenney R, Gam A, et al. (1999) Evidence that the high incidence of treatment failures in Indian Kala-Azar is due to the emergence of antimony-resistant strains of . J Infect Dis 180: 564–567.
[7]
Nadim A, Javadian E, Seyedi-Rashti M (1994) Epidemiology of leishmaniasis in Iran. In: Ardehali S, Rezai HR, Nadim A, editors. Leishmania parasite and leishmaniases, 2nd edition. Tehran: Iran University Press. pp. 178–180.
[8]
Mohebali M, Javadian E, Yaghoobi-Ershadi MR, Akhavan AA, Abaei MR, et al. (2004) Characterization of Leishmania infection in rodents from endemic areas of the Islamic Republic of Iran. East Mediterr Health J 10: 591–599.
[9]
Yaghoobi-Ershadi MR, Jafari R, Hanafi-Bojd AA (2004) A new epidemic focus of zoonotic cutaneous leishmaniasis in central Iran. Ann Saudi Med 24: 98–101.
[10]
Sharifi I, Fekri AR, Aflatonian MR, Nadim A, Nikian Y, et al. (1998) Cutaneous leishmaniasis in primary school children in the south-eastern Iranian city of Bam, 1994–95. Bull World Health Organ 76: 289–293.
[11]
Yaghoobi-Ershadi MR, Hanafi-Bojd AA, Javadian E, Jafari R, Zahraei-Ramazani AR, et al. (2002) A new focus of cutaneous leishmaniasis caused by . Saudi Med J 23: 291–294.
[12]
Momeni AZ, Jalayer T, Emamjomeh M, Khamesipour A, Zicker F, et al. (1999) A randomised, double-blind, controlled trial of a killed vaccine plus BCG against zoonotic cutaneous leishmaniasis in Iran. Vaccine 17: 466–472.
Hajjaran H, Mohebali M, Razavi MR, Rezaei S, Kazemi B, et al. (2004) Identification of Leishmania species isolated from human cutaneous leishmaniasis in Mashhad city using random amplified polymorphic DNA (RAPD-PCR). Iran J Public Health 33: 8–15.
[15]
Evans D (1989) Handbook of isolation, characterization and cryopreservation of Leishmania . New York: UNDP/World Bank/WHO. pp. 2–9.
[16]
Mauricio IL, Gaunt MW, Stothard JR, Miles MA (2001) Genetic typing and phylogeny of the complex by restriction analysis of PCR amplified gp63 intergenic regions. Parasitology 122: 393–403.
[17]
Nare B, Luba J, Hardy LW, Beverley S (1997) New approaches to Leishmania chemotherapy: Pteridine reductase 1 (PTR1) as a target and modulator of antifolate sensitivity. Parasitology 114: S101–S110.
[18]
Ouellette M, Drummelsmith J, El Fadili A, Kundig C, Richard D, et al. (2002) Pterin transport and metabolism in Leishmania and related trypanosomatid parasites. Int J Parasitol 32: 385–398.
[19]
Grondin K, Papadopoulou B, Ouellette M (1993) Homologous recombination between direct repeat sequences yields P-glycoprotein containing amplicons in arsenite resistant Leishmania. Nucleic Acids Res 21: 1895–1901.
[20]
Roy G, Dumas C, Sereno D, Wu Y, Singh AK, et al. (2000) Episomal and stable expression of the luciferase reporter gene for quantifying spp. infections in macrophages and in animal models. Mol Biochem Parasitol 110: 195–206.
[21]
Sereno D, Roy G, Lemesre JL, Papadopoulou B, Ouellette M (2001) DNA transformation of axenic amastigotes and their use in drug screening. Antimicrob Agents Chemother 45: 1168–1173.
[22]
El Fadili A, Kundig C, Ouellette M (2002) Characterization of the folylpolyglutamate synthetase gene and polyglutamylation of folates in the protozoan parasite Leishmania. Mol Biochem Parasitol 124: 63–71.
[23]
Breton M, Tremblay MJ, Ouellette M, Papadopoulou B (2005) Live nonpathogenic parasitic vector as a candidate vaccine against visceral leishmaniasis. Infect Immun 73: 6372–6382.
[24]
Ouellette M, Fase-Fowler F, Borst P (1990) The amplified H circle of methotrexate-resistant contains a novel P-glycoprotein gene. EMBO J 9: 1027–1033.
[25]
Abdo MG, Elamin WM, Khalil EA, Mukhtar MM (2003) Antimony-resistant in eastern Sudan: Incidence and in vitro correlation. East Mediterr Health J 9: 837–843.
[26]
Haimeur A, Brochu C, Genest P, Papadopoulou B, Ouellette M (2000) Amplification of the ABC transporter gene PGPA and increased trypanothione levels in potassium antimonyl tartrate (SbIII) resistant . Mol Biochem Parasitol 108: 131–135.
[27]
El Fadili K, Messier N, Leprohon P, Roy G, Guimond C, et al. (2005) Role of the ABC transporter MRPA (PGPA) in antimony resistance in axenic and intracellular amastigotes. Antimicrob Agents Chemother 49: 1988–1993.
[28]
Dube A, Singh N, Sundar S, Singh N (2005) Refractoriness to the treatment of sodium stibogluconate in Indian Kala-Azar field isolates persist in in vitro and in vivo experimental models. Parasitol Res 96: 216–223.
[29]
Ouellette M, Drummelsmith J, Papadopoulou B (2004) Leishmaniasis: Drugs in the clinic, resistance and new developments. Drug Resist Updat 7: 257–266.
[30]
Santos Ferreira C, Martins PS, Demicheli C, Brochu C, Ouellette M, et al. (2003) Thiol-induced reduction of antimony(V) into antimony(III): A comparative study with trypanothione, cysteinyl-glycine, cysteine and glutathione. Biometals 16: 441–446.
[31]
Sereno D, Cavaleyra M, Zemzoumi K, Maquaire S, Ouaissi A, et al. (1998) Axenically grown amastigotes of used as an in vitro model to investigate the pentavalent antimony mode of action. Antimicrob Agents Chemother 42: 3097–3102.
[32]
Shaked-Mishan P, Ulrich N, Ephros M, Zilberstein D (2001) Novel intracellular SbV reducing activity correlates with antimony susceptibility in . J Biol Chem 276: 3971–3976.
[33]
Zhou Y, Messier N, Ouellette M, Rosen BP, Mukhopadhyay R (2004) Leishmania major LmACR2 is a pentavalent antimony reductase that confers sensitivity to the drug Pentostam. J Biol Chem 279: 37445–37451.
[34]
Denton H, McGregor JC, Coombs GH (2004) Reduction of anti-leishmanial pentavalent antimonial drugs by a parasite-specific thiol-dependent reductase TDR1. Biochem J 1: 405–412.
[35]
Dey S, Papadopoulou B, Haimeur A, Roy G, Grondin K, et al. (1994) High level arsenite resistance in is mediated by an active extrusion system. Mol Biochem Parasitol 67: 49–57.
[36]
Haimeur A, Ouellette M (1998) Gene amplification in selected for resistance to sodium stibogluconate. Antimicrob Agents Chemother 42: 1689–1694.
[37]
Mukhopadhyay R, Dey S, Xu N, Gage D, Lightbody J, et al. (1996) Trypanothione overproduction and resistance to antimonials and arsenicals in Leishmania. Proc Natl Acad Sci U S A 93: 10383–10387.
[38]
Carter KC, Sundar S, Spickett C, Pereira OC, Mullen AB (2003) The in vivo susceptibility of to sodium stibogluconate is drug specific and can be reversed by inhibiting Glutathione biosynthesis. Antimicrob Agents Chemother 47: 1529–1535.
[39]
Olliaro PL, Bryceson ADM (1993) Practical progress and new drugs for changing patterns of leishmaniasis. Parasitol Today 9: 323–328.
[40]
Croft SL (2001) Monitoring drug resistance in leishmaniasis. Trop Med Int Health 6: 899–905.
[41]
Sundar S (2001) Drug resistance in Indian visceral leishmaniasis. Trop Med Int Health 6: 849–854.
[42]
Berman JD, Wyler DJ (1980) An in vitro model for investigation of chemotherapeutic agents in leishmaniasis. J Infect Dis 142: 83–86.
[43]
Ibrahim ME, Hag-Ali M, el-Hassan AM, Theander TG, Kharazmi A (1994) Leishmania resistant to sodium stibogluconate: Drug-associated macrophage-dependent killing. Parasitol Res 80: 569–574.
[44]
Faraut-Gambarelli F, Piarroux R, Deniau M, Giusiano B, Marty P, et al. (1997) In vitro and in vivo resistance of to meglumine antimoniate: A study of 37 strains collected from patients with visceral leishmaniasis. Antimicrob Agents Chemother 41: 827–830.
[45]
Sharifi I, FeKri AR, Aflatonian MR, Khamesipour A, Nadim A, et al. (1998) Randomised vaccine trial of single dose of killed plus BCG against anthroponotic cutaneous leishmaniasis in Bam, Iran. Lancet 351: 1540–1543.
[46]
Gourbal B, Sonuc N, Bhattacharjee H, Legare D, Sundar S, et al. (2004) Drug uptake and modulation of drug resistance in Leishmania by an aquaglyceroporin. J Biol Chem 279: 31010–31017.
[47]
Ouellette M, Haimeur A, Grondin K, Legare D, Papadopoulou B (1998) Amplification of ABC transporter gene PGPA and of other heavy metal resistance genes in and their study by gene transfection and gene disruption. Methods Enzymol 292: 182–193.
[48]
Haimeur A, Guimond C, Pilote S, Mukhopadhyay R, Rosen BP, et al. (1999) Elevated levels of polyamines and trypanothione resulting from overexpression of the ornithine decarboxylase gene in arsenite-resistant Leishmania. Mol Microbiol 34: 726–735.
[49]
Guimond C, Trudel N, Brochu C, Marquis N, Fadili AE, et al. (2003) Modulation of gene expression in Leishmania drug-resistant mutants as determined by targeted DNA microarrays. Nucleic Acids Res 31: 5886–5896.
[50]
Marquis N, Gourbal B, Rosen BP, Mukhopadhyay R, Ouellette M (2005) Modulation in aquaglyceroporin AQP1 gene transcript levels in drug-resistant Leishmania. Mol Microbiol 57: 1690–1699.
[51]
Decuypere S, Rijal S, Yardley V, De Doncker S, Laurent T, et al. (2005) Gene expression analysis of the mechanism of natural Sb(V) Resistance in isolates from Nepal. Antimicrob Agents Chemother 49: 4616–4621.
[52]
Ashutosh , Gupta S, Ramesh , Sundar S, Goyal N (2005) Use of field isolates expressing the luciferase reporter gene in in vitro drug screening. Antimicrob Agents Chemother 49: 3776–3783.
[53]
Bishai WR (2005) Clinical significance of pneumococcal resistance and factors influencing outcomes. Treat Respir Med 4: Suppl 119–23.
[54]
French GL (2005) Clinical impact and relevance of antibiotic resistance. Adv Drug Deliv Rev 57: 1514–1527.
[55]
Niederman MS (2001) Impact of antibiotic resistance on clinical outcomes and the cost of care. Crit Care Med 29: N114–N120.
